Clinical trials: Nonrecurrent Condyloma
Recurrent Condyloma, Nonrecurrent Condyloma
Recurrent and Nonrecurrent Condyloma Treatment
Treatment is considered successful if the difference in the response in the reduction of the affected area is above 30% for any of the doses compared to placebo Patients will be randomised to 1 of 3 treatment arms 1. Placebo 2.
- Trial name
- NCT01639638
- Testing
- PROAPOPTOTIC PEPTIDE CIGB 300
- Where
- Argentina
- Volunteers
- 132 people
- Sponsor
- Laboratorio Elea Phoenix S.A.